Physician profile
Mohammad A Khan
NPI 1194792382
$3,600.99
in general payments reported to CMS, 2019-2025
30 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $30.91 · 2021: $142 · 2022: $246 · 2023: $833 · 2024: $1,014 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.72 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $497.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $488.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $434.30 | 2022-2025 | |
| Lilly USA, LLC | $341.54 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $242.45 | 2019-2024 | |
| Dexcom, INC. | $177.45 | 2024-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $149.27 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $137.29 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abiomed | $128.66 | 2021 | |
| W. L. Gore & Associates, INC. | $127.68 | 2019 | |
| Exact Sciences Corporation | $124.23 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $74.65 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.63 | 2024-2025 | Jardiance |
| Abbott Laboratories | $70.67 | 2022-2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.03 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $58.40 | 2023 | Gvoke Hypopen |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.08 | 2025 | Lifevest |
| Hologic Sales and Service, LLC | $45.06 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Amgen INC. | $43.29 | 2023-2024 | Otezla, Repatha |
| Ge Healthcare | $32.21 | 2024-2025 | |
| Sanofi Pasteur INC. | $30.50 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.54 | 2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $28.90 | 2022 | |
| Axsome Therapeutics, INC. | $27.97 | 2025 | Auvelity |
| Insulet Corporation | $24.49 | 2025 | Omnipod |
| Idorsia Pharmaceuticals US INC | $22.10 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $21.89 | 2023 | Vaxneuvance, Gardasil 9 |
| Phadia US INC. | $17.17 | 2024 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.49 | 2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $15.21 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.